Research Article
Sleep Disturbance and Related Factors in the Patients with Relapsing-Remitting Multiple Sclerosis
Table 3
The use of DMT: a comparison between the study subgroups.
| | Subgroup with sleep disturbances () | Subgroup without sleep disturbances () | value |
| | DMT | Fingolimod | 4 | 3 | 0.866 | | Dimethyl fumarate | 25 | 25 | 0.054 | | Interferon beta-1a | 8 | 5 | 0.981 | | Interferon beta-1b | 30 | 23 | 0.409 | | Natalizumab | 2 | 0 | — | | Ocrelizumab | 2 | 1 | — | | Glatiramer acetate | 19 | 6 | 0.103 | | Peginterferon beta-1a | 4 | 2 | — | | Teriflunomide | 15 | 4 | 0.095 |
|
|
